Glaukos Co. (NYSE:GKOS) Shares Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D increased its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 26.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,883 shares of the medical instruments supplier's stock after buying an additional 8,884 shares during the period. State of New Jersey Common Pension Fund D owned about 0.09% of Glaukos worth $3,329,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in GKOS. GAMMA Investing LLC acquired a new position in Glaukos during the 4th quarter worth approximately $55,000. CWM LLC grew its holdings in Glaukos by 309.5% during the 3rd quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier's stock worth $104,000 after acquiring an additional 1,046 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Glaukos by 17.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier's stock worth $137,000 after acquiring an additional 270 shares in the last quarter. Mackenzie Financial Corp acquired a new position in Glaukos during the 3rd quarter worth approximately $203,000. Finally, Xponance Inc. acquired a new position in Glaukos during the 3rd quarter worth approximately $208,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Performance

GKOS stock traded down $0.63 on Friday, hitting $99.48. The company's stock had a trading volume of 288,895 shares, compared to its average volume of 481,113. The firm has a 50 day moving average of $92.42 and a two-hundred day moving average of $81.74. Glaukos Co. has a 1 year low of $45.38 and a 1 year high of $103.66. The stock has a market cap of $4.99 billion, a price-to-earnings ratio of -35.78 and a beta of 1.08. The company has a current ratio of 5.34, a quick ratio of 4.78 and a debt-to-equity ratio of 0.77.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.07). The firm had revenue of $82.40 million for the quarter, compared to analysts' expectations of $81.00 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The firm's quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.53) EPS. Equities analysts predict that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on GKOS shares. Stifel Nicolaus restated a "buy" rating and issued a $110.00 target price on shares of Glaukos in a report on Wednesday, April 3rd. Truist Financial restated a "buy" rating and issued a $110.00 target price on shares of Glaukos in a report on Monday, April 8th. StockNews.com cut shares of Glaukos from a "hold" rating to a "sell" rating in a report on Tuesday, February 27th. Citigroup upped their target price on shares of Glaukos from $107.00 to $120.00 and gave the company a "buy" rating in a report on Monday, March 25th. Finally, Needham & Company LLC upped their target price on shares of Glaukos from $105.00 to $108.00 and gave the company a "buy" rating in a report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $99.80.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 474 shares of the company's stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total transaction of $42,835.38. Following the completion of the transaction, the chief financial officer now owns 54,916 shares in the company, valued at approximately $4,962,758.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Alex R. Thurman sold 474 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total value of $42,835.38. Following the completion of the transaction, the chief financial officer now owns 54,916 shares in the company, valued at approximately $4,962,758.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alex R. Thurman sold 1,372 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $100.54, for a total transaction of $137,940.88. Following the completion of the transaction, the chief financial officer now owns 52,532 shares of the company's stock, valued at approximately $5,281,567.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 242,357 shares of company stock worth $22,857,372. 6.40% of the stock is owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.